文献速递乳腺癌

循环肿瘤DNA评估乳腺癌微小残留病:超灵敏检测研究

The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease.
PubMed 文献 · J Clin Oncol · 2026-03-10

Pathologic Response Evaluation and Detection in Circulating Tumor-DNA研究是一项前瞻性多中心研究,评估肿瘤指导的超灵敏ctDNA检测(<100 ppm)在II/III期HER2阳性或三阴性乳腺癌新辅助治疗后的应用。主要终点未达到:新辅助治疗后ctDNA阴性预测pCR的NPV仅60%(95%CI 0.50-0.69),但ctDNA阳性独立于pCR预测复发(HR 8.9),术后ctDNA阳性者复发风险极高(HR 128)。

要点

  • 新辅助治疗后ctDNA阴性不能区分pCR与非pCR,NPV为60%。
  • 新辅助治疗后ctDNA可检测者复发风险显著升高(HR 8.9),独立于pCR。
  • 术后ctDNA阳性者复发风险极高(HR 128),阴性者5年IDFS达94%。

核心结论

  • 在HER2阳性乳腺癌和三阴性乳腺癌中,新辅助治疗后ctDNA不能区分pCR与非pCR。
  • 但ctDNA提供显著更优的预后分层,可识别结局极好和风险极高的患者。
  • 这些发现支持ctDNA指导的治疗降阶和升阶策略。

研究设计与样本

  • Pathologic Response Evaluation and Detection in Circulating Tumor-DNA是一项前瞻性、多中心研究。
  • 采用肿瘤指导的超灵敏ctDNA检测(<100 ppm)评估治疗反应生物标志物。
  • 共入组227例患者,220例可评估pCR(48% HER2阳性,52% TNBC),91例(41%)达到pCR。
  • ctDNA在基线、新辅助治疗后术前、术后三个时间点评估。

主要发现

  • 主要终点未达到:新辅助治疗后ctDNA对pCR的NPV为60%(95%CI 0.50-0.69),40%非pCR患者ctDNA阴性。
  • 术后ctDNA阴性者5年IDFS为94%。

关键数值与推荐

  • 主要终点:新辅助治疗后ctDNA对pCR的NPV需≥90%,实际为60%(95%CI 0.50-0.69),未达到。
  • TNBC队列预设次要终点:新辅助治疗后ctDNA与5年IDFS的关联达到。

临床怎么用

  • 新辅助治疗后ctDNA阴性不能替代病理评估判断pCR,不应据此降阶治疗。
  • 术后ctDNA阳性提示极高复发风险,可考虑治疗升阶策略。
  • 术后ctDNA阴性且5年IDFS达94%,支持在部分患者中探索治疗降阶。

局限性

  • 主要终点未达到,ctDNA对pCR的阴性预测价值有限。
  • 研究聚焦II/III期HER2阳性或TNBC,结论不能外推至其他亚型或分期。
  • 原文未报告检测的具体性能参数及随访时长等细节。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Patients with stage II/III human epidermal growth factor receptor 2 (HER2)-positive or triple-negative breast cancer (TNBC) frequently receive neoadjuvant therapy (NAT). Although pathologic complete response (pCR) correlates with improved outcomes, many non-pCR patients have long-term survival. Circulating tumor-DNA (ctDNA) minimal residual disease (MRD) assessment may provide additional or superior risk stratification. METHODS: Pathologic Response Evaluation and Detection in Circulating Tumor-DNA is a prospective, multicenter study evaluating ctDNA as a biomarker of treatment response using a tumor-informed, ultrasensitive (<100 parts per million) assay. The primary objective was to determine whether the negative predictive value (NPV) of post-NAT ctDNA for pCR was ≥90%. A prespecified secondary objective for the TNBC cohort was to assess associations between ctDNA and 5-year invasive disease-free survival (IDFS). ctDNA was evaluated at baseline, after NAT before surgery, and after surgery. RESULTS: Of 227 enrolled patients, 220 were evaluable for pCR (48% HER2-positive; 52% TNBC) and 91 patients (41%) had pCR. The primary objective was not met. Although all patients with pCR were ctDNA-negative after NAT, 40% of non-pCR patients were also ctDNA-negative (NPV, 60% [95% CI, 0.50 to 0.69]). However, the prespecified secondary objective was met. Detectable ctDNA after NAT was prognostic for recurrence (hazard ratio [HR], 8.9 [95% CI, 2.4 to 33]; P = .001), independent of pCR. Additionally, detectable ctDNA after surgery identified patients at extremely high recurrence risk (HR, 128 [95% CI, 15 to 1,083]; P < .001), while ctDNA-negative patients after surgery had 94% 5-year IDFS. CONCLUSION: In HER2-positive breast cancer and TNBC, ctDNA after NAT does not discriminate pCR from non-pCR. However, ctDNA provides markedly superior prognostic stratification, identifying patients with exceptional outcomes and those at extreme risk. These findings support ctDNA-guided therapeutic de-escalation and escalation strategies.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Hunter NB, Parsons HA, Cope L, et al. The Pathologic Response Evaluation and Detection in Circulating Tumor-DNA Study: Ultrasensitive Circulating Tumor-DNA Assessment of Breast Cancer Minimal Residual Disease. J Clin Oncol. 2026. PMID: 41805422. doi:10.1200/JCO-25-02934

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。